Amsterdam, the Netherlands -- DSM NV and DuPont are to form a 50:50 joint venture in advanced surgical biomedical materials, Actamax Surgical Materials llc.
The joint venture, which is waiting for European Union regulatory approval, will cover the market for surgical sealants, adhesion barriers and tissue adhesives.
A joint statement said this large and underserved market involves over 100 million annual surgical procedures worldwide, and noted that "The outcome of many surgical procedures could be positively impacted using next-generation materials under development by the joint venture."
The announcement said Actamax will build a comprehensive biomedical product portfolio using "patent-protected biodegradable hydrogel technologies," but did not mention specific materials. It did say that early technology was developed using DuPont materials science and biotechnology capabilities, and that commercialisation will rely on the medical polymer processing and manufacturing capabilities of DSM.
DSM has a biomaterials business which includes various urethanes materials ranging from thermoplastic polycarbonate-urethanes and other TPUs to segmented PUs and thermoplastic silicone-polyether-
DuPont and DSM say the JV's activities fit with DSM's biomedical materials portfolio where it has "rapidly built a leading position in the past few years."
DuPont said Actamax Surgical Materials is a strategic part of its DuPont Applied BioSciences business, which integrates biotechnology with other sciences to create products that can transform large, addressable markets.
The joint venture will, the companies said, focus on clinical validation of the products and technology, and commercialisation, including the manufacture of proprietary products. It will also aim to set up development relationships with leading medical device companies.
"The cooperation with DuPont is a great way to further boost our activities in the biomedical field," said Christophe J. Dardel, president DSM Biomedical, in the statement. "In line with our open innovation strategy, this will allow us to combine the strengths of two leading companies to develop solutions to better address patient needs through material innovations."
"Our platform of technologies will offer physicians and patients improved outcomes of surgery that will prevent post-operative complications while reducing healthcare costs," said John Ranieri, vice president DuPont Applied BioSciences. "Actamax will deliver a number of products that can be optimized for different surgical situations and clinical needs. The success DSM has had in the biomedical materials market makes them an ideal strategic partner for us to commercialise our technology portfolio."